The role of Zika virus (ZIKV) immunity on subsequent dengue virus (DENV) infections is 35 relevant to anticipate the dynamics of forthcoming DENV epidemics in areas with previous ZIKV 36 exposure. We study the effect of ZIKV infection with various strains on subsequent DENV 37 immune response after 10 and 2 months of ZIKV infection in rhesus macaques. Our results 38
adults ( Supplementary Fig. 1k ), that were challenged with DENV-2 (NGC-44 strain), monitored 144 and bled for three months (Fig. 1) . Two cohorts were previously exposed to ZIKV: cohort 1 145 (ZIKVPF-10mo) was comprised of 4 animals that had been exposed to ZIKV H/PF/2013 strain 146 10 months before DENV-2 challenge (mid-convalescence), and cohort 2 (ZIKVPR-2mo) 147 comprised of 6 animals that had been exposed to ZIKV PRVABC59 strain two months before 148 DENV-2 challenge (early-convalescence). Both ZIKV strains used for previous exposure of 149 these groups are >99.99% comparable in amino acid identity ( Supplementary Table 1 ). An 150 additional cohort 3 (Naïve) included four animals naïve to ZIKV/DENV as a control group. After 151 DENV challenge all macaques were extensively monitored and sample collection was 152 performed at various timepoints up to 90 days post infection (dpi) for serum and PBMCs 153 isolation. 154
The clinical status was monitored to determine if the presence of ZIKV immunity affected 155 the clinical outcome of DENV infection. Vital signs such as weight (kg), and temperature (°C) 156 were monitored. Also, complete blood cell counts (CBC), and comprehensive metabolic panel 6 each group ( Supplementary Fig. 1c-g) . CMP levels showed no differences in alkaline 164 phosphatase and aspartate transaminase (AST) ( Supplementary Fig. 1h-i) . Although within the 165 normal range, levels of alanine transaminase (ALT) were significantly higher in the ZIKVPR-2mo 166 group compared to its baseline at 7 dpi (p=0.0379, Two-way Anova Dunnett test), but at 15 and 167 30 dpi values returned to baseline levels ( Supplementary Fig. 1j ). Overall, except for the 168 isolated increase of ALT at 7 dpi in ZIKVPR-2mo, the clinical profile suggests that the presence 169 of ZIKV-immunity did not significantly influence the clinical outcome of DENV infection. 170 171 DENV RNAemia not enhanced by previous ZIKV immunity. RNAemia levels in NHPs serum 172
were quantified by qRT-PCR at baseline, 1 to 10, and 15 dpi to determine if the presence of 173 early-(ZIKVPR-2mo) or mid-convalescence (ZIKVPF-10mo) to ZIKV alters DENV RNAemia 174 kinetics. No significant differences between groups were observed in detected levels of DENV 175 genome copies per ml of serum overtime ( Fig. 2a ). We noted that in the ZIKVPF-10mo group 3 176 out of 4 animals were able to keep the RNAemia level below 10 3 genome copies the next day 177 after DENV infection. This group started an early clearance of the RNAemia at 7 dpi, with only 1 178 out of 4 animals having detectable levels by days 8 and 9 pi. For ZIKVPR-2mo and naïve 179 animals, the clearance of detectable RNAemia started at 8 dpi, in 4 out of 6 and 1 out of 4 of the 180 animals, respectively. Naïve animals had the most delayed clearance of RNAemia with at least 181 half of the animals with detectable levels of viral RNA until day 9 pi. RNAemia was completely 182 resolved in all animals by 10 dpi. In summary, ZIKVPF-10mo had 7.25, ZIKVPR-2mo 7.5, and 183 naïve animals 8 mean days of detectable RNAemia after DENV infection (Fig. 2b ). In addition, 184 the area under the curve (AUC) was calculated but no statistically significance differences were 185 observed in the RNAemia peak among groups ( Supplementary Fig. 2 ). However, the AUC trend 186 to be lower in both ZIKV-immune groups. In terms of the kinetics, a delay in the peak RNAemia 187 set point was observed in both ZIKV-immune groups (switch from day 2 to days 5 and 6) 188 followed by higher, but non-significant, levels compared to the naïve group, and a subsequent 189 early RNAemia clearance in both ZIKV-immune groups. Together these results show that, 190 although no statistically significant differences among groups were observed, previous immunity 191 to ZIKV is not associated with an increase in DENV RNAemia; even more, a mid-convalescence 192 to ZIKV tended to develop a shorter viremic period. 193 194 Pro-inflammatory cytokines not exacerbated by ZIKV immunity. To determine if the 195 characterized cytokine profile of an acute DENV infection was modulated by ZIKV immunity we 196 assessed the serum concentration (pg/ml) of 8 cytokines/chemokines by Luminex multiplex at 197 baseline, 1, 2, 3, 5, 10, 15 and 30 dpi. The naïve group showed significant higher levels of Type 198 I interferon alpha (IFN-α) and pro-inflammatory cytokines such as Interleukin-6 (IL-6), and 199 monokine induced by IFN-gamma (MIG/CXCL9) ( Fig. 3a-c ). IFN-α was highest at 5 dpi ( Fig. 3a:  200 p<0.0001 vs ZIKVPF-10mo and p=0.0003 vs ZIKVPR-2mo, Two-way Anova Tukey test). has been demonstrated to be involved in the innate anti-viral immunity and elevated levels are 202 associated with higher viral load and antigen availability. IL-6, a multifunctional cytokine involved 203 in immune response regulation and many inflammatory reactions showed the highest levels at 1 204 dpi in naïve animals ( Fig. 3b: p=0 .0115 vs ZIKVPF-10mo and p=0.0185 vs ZIKVPR-2mo, Two-205 way ANOVA Tukey test). Finally, MIG/CXCL9, which is a potent chemoattractant involved in 206 leucocyte trafficking demonstrated the highest levels at 10 dpi in naïve animals ( Fig. 3c : 207 p=0.0004 vs ZIKVPR-2mo, Two-way Anova Tukey test). On the other hand, the mid-208 convalescent ZIKVPF-10mo group showed higher levels of CXCL10 (IP-10) ( Fig. 3g ) at day 1 209 (p=0.0198 vs ZIKVPR-2mo, Two-way Anova Tukey test), 5 (p=0.0487 vs Naïve, Two-way 210 Anova Tukey test) and 10 pi (p=0.0009 vs ZIKVPR-2mo, Two-way Anova Tukey test). CXCL10 211 is a T cell-activating chemokine and chemoattractant for many other immune cells. Also, this 212 group showed higher levels of perforin ( Fig. 3h ) at day 10 (p=0.0024 vs Naïve and p=0.0190 vs 213 ZIKVPR-2mo, Two-way Anova Tukey test) and 15 pi (p=0.0178 vs Naïve, Two-way Anova 214 Tukey test). Perforin is an effector cytolytic protein released by activated cytotoxic CD8+ T cells 215 and natural killer (NK) cells. No significant differences between groups were observed for other 216 pro-inflammatory citokines such as monocyte chemoattractant protein 1 (MCP-1), macrophage 217 inflammatory protein 1-beta (MIP-1β) and IL-1 receptor antagonist (IL-1RA) ( Fig. 3d-f ). 218
Collectively, these results demonstrate that the presence of ZIKV immunity does not exacerbate 219 pro-inflammatory status after DENV infection while mid-convalescence immunity to ZIKV 220 stimulated levels of mediators mainly involved in the activation of cell-mediated immune 221 response. 222 223 DENV and ZIKV cross-reactive antibody response. An ELISA-based serological profile was 224 performed to determine the contribution of ZIKV immunity in the cross-reactive Ab response 225 before and after DENV infection. We assessed the levels of DENV IgM and IgG, and cross-226 reactivity with ZIKV (IgM, IgG, NS1-IgG and EDIII-IgG) at multiple timepoints (Supplementary 227 Fig. 3 ). Naïve cohort showed a significant higher peak of IgM ( Supplementary Fig. 3a ) 228 characteristic of a primary DENV infection at 15 and 30 dpi (p<0.0001 vs ZIKVPF-10mo and 229 p=0.0004 vs ZIKVPR-2mo, p=0.0044 vs ZIKVPF-10mo and p=0.0179 vs ZIKVPR-2mo, 230 respectively, Two-way Anova Tukey test). This indicates the productive and acute DENV 231 infection, while ZIKV immune groups showed lower levels of IgM resembling a heterotypic 232 secondary infection. Total DENV IgG levels ( Supplementary Fig. 3b ) of both ZIKV-immune 233 groups were significantly higher compared to naïve since baseline (cross-reactive ZIKV-IgG 234 Abs) and 7, 15, 30, 60 and 90 (the latter for ZIKVPF-10mo only) (ZIKVPF-10mo vs Naïve: 235 p=0.0010, p<0.0001, p<0.0001, p<0.0001, p<0.0001, p=0.0016; ZIKVPF-2mo vs Naïve: 236 p=0.0029, p=0.0002, p<0.0001, p<0.0001, p=0.0006; Two-way Anova Tukey test). The ZIKVPF-237 10mo group showed significant higher levels than ZIKVPR-2mo group at 30 and 90 dpi 238 (p=0.0242 and p=0.0348, Two-way Anova Tukey test). Overall, ZIKVPF-10mo developed higher 239 and long-lasting levels of DENV IgG. 240
In contrast, ZIKV IgM levels were under or near the limit of detection in all groups over 241 time after DENV infection despite several significant differences between groups 242 ( Supplementary Fig. 3c ). ZIKV IgG levels ( Supplementary Fig. 3d ) were high in both ZIKV-243 immune groups at baseline and 7 dpi compared to naive (p<0.0001 vs naïve, Two-way Anova 244
Tukey test), suggesting that although different pre-infecting ZIKV strains, the previous elicited 245
IgG response against both ZIKV strains is comparable. After DENV infection, an increase of 246 ZIKV IgG was shown and remain constantly high at 15, 30, 60 and 90 dpi in both ZIKV-immune 247 groups (p<0.0001 vs naïve for all timepoints, Two-way Anova Tukey test), suggesting that 248 DENV has the potential to stimulate ZIKV-binding Ab-producing plasmablasts. In addition, to 249 elucidate the composition of similar ZIKV IgG levels in ZIKV-immune groups, we measured 250 ZIKV-specific NS1 IgG ( Supplementary Fig. 3e ) and ZIKV-specific EDIII IgG (Supplementary 251 Fig. 3f ) levels. Although ZIKVPR-2mo showed significant differences compared to naïve at 30, 252 60 and 90 dpi (p<0.0001, p=0.0001, p=0.0159; Two-way Anova Tukey test), we observed a 253 significantly higher expansion and long-lasting response of ZIKV NS1-specific Abs in the 254 ZIKVPF-10mo group compared to the ZIKVPR-2mo group at baseline, 60 and 90 dpi (p=0.0036, 255 p=0.0071, p=0.0294; Two-way Anova Tukey test) and also compared to naïve animals at all 256 timepoints (p<0.0001, Two-way Anova Tukey test). Moreover, higher magnitude of ZIKV-257 specific EDIII-IgG levels in the ZIKVPF-10mo group than in the ZIKVPR-2mo group was 258 observed compared to naïve at baseline (ZIKVPF-10mo only), 15, 30 and 60 (ZIKVPF-10mo vs 259 Naïve: p=0.0092, p<0.0001, p<0.0001, p=0.0034; ZIKVPR-2mo vs Naïve: p=0.0003, p=0.0014, 260 p=0.0055; Two-way Anova Tukey test), suggesting that a ZIKV mid-convalescence promotes an 261 expansion of higher magnitude of ZIKV EDIII-IgG Abs from ZIKV memory B cells (MBC). 262
However, those higher cross-reacting levels decrease overtime as expected. In summary, a 263 boost of DENV and ZIKV Abs is triggered by the presence of ZIKV immunity and the expansion 264 of specific-and cross-reactive Abs is higher on magnitude and durability when a mid-265 convalescence immunity to ZIKV is present. 266 267 DENV neutralization is boosted by ZIKV immunity. Neutralizing antibodies (NAbs) are 268 essential to combat DENV and ZIKV infection. The maturation and potency of this response is 269 known to define to a great extent the infection outcome 11, 47 . Accordingly, we tested the 270 neutralization capacity of NAbs in serum from ZIKV-immune and naïve animals before and after 271 DENV infection, to determine whether an early-or mid-convalescence to ZIKV affected the NAb 272 response. Plaque Reduction Neutralization Test (PRNT) was performed to elucidate the NAb 273 titers of all groups against all DENV serotypes and both ZIKV pre-infecting strains. Before 274 infection with DENV the naïve groups had no detectable NAb levels (<1:20 PRNT60 titers) 275 against all DENV serotypes, while ZIKV-immune groups showed low cross-NAb titers against 276 DENV-2 and DENV-4 ( Fig. 4a) . These cross-reactive levels were higher in the ZIKVPF-10mo 277 group than in the ZIKVPR-2mo group for both viruses. The peak of high NAb titers occurred at 278 30 days after DENV infection for all groups (ZIKVPF-10mo>ZIKVPR-2mo>Naïve) against all 279 DENV serotypes (DENV-2>DENV-4>DENV-3>DENV-1) (Fig. 4b ). The ZIKVPF-10mo group 280 neutralized all DENV serotypes with significant higher potency than naïve animals (p<0.0001, 281 p=0.0337, p<0.0001, p<0.0001 for DENV1-4; Two-way Anova Tukey test) and the ZIKVPR-2mo 282 group, except for DENV-2, that both ZIKV-immune groups have comparable neutralization 283 magnitude at 30 dpi (p=0.0002, p=0.7636, p=0.0016, p=0.0004 for DENV1-4; Two-way Anova 284 Tukey test). However, the neutralization kinetics by sigmoidal response curves suggest higher 285 percent of neutralization against DENV-2 overtime in the group with mid-convalescence to ZIKV 286 ( Supplementary Fig. 4 ). On the other hand, the ZIKVPR-2mo group showed significantly higher 287 potency of the NAb response only against DENV-1 compared to naive animals (p=0.0146; Two-288 way Anova Tukey test) ( Fig. 4b) .
289
In addition, we tested whether the NAb titers that peak at 30 dpi for all groups remain 290 constant over time (up to 90 dpi) against all DENV serotypes ( Fig. 4c-f ). In general, the 291 neutralizing response of the ZIKVPF-10mo maintained higher NAb titers up to 90 dpi compared 292 to ZIKVPR-2mo and naïve groups. Significant differences between ZIKVPF-10mo and ZIKVPR-293 2mo groups were observed against DENV-1,-3 and -4 at day 30 pi (p=0.0002, p=0.0016, 294 p=0.0004; Two-way Anova Tukey test) and at day 60 pi against DENV-2 and DENV-3 295 (p=0.0179, p=0.0047; Two-way Anova Tukey test). The neutralizing Ab response of the 296 ZIKVPF-10mo group was even more significantly higher compared to the naïve group at day 15 297 (only performed for the infecting serotype to monitor early neutralizing activity), day 30, 60 and 298 90 pi against DENV-2 (p=0.0022, p=0.0337, p=0.0146, p=0.0337; Two-way Anova Tukey test); 299 at day 30 pi against DENV-1 (p<0.0001, Two-way Anova Tukey test); at day 30 and 60 pi 300 against DENV-3 (p<0.0001, Two-way Anova Tukey test); and at day 30 pi against DENV-4 301 (p<0.0001, Two-way Anova Tukey test). In contrast, the ZIKVPR-2mo group showed a 302 neutralizing Ab response with a magnitude and long-lasting levels comparable to the naïve 303 group, except at day 15 and 30 pi against DENV-2 and DENV-1, respectively (p=0.0067, 304 p=0.0146; Two-way Anova Tukey test). The neutralizing response was long-lasting in the 305 ZIKVPF-10mo group compared to other groups as supported by the data from days 30 and 60 306 p.i. At day 90 pi, although no significant differences were observed between all groups, the 307 ZIKVPF-10mo group showed a consistent trend to maintain higher NAb titers against all DENV 308 serotypes indicating a higher and long-lasting breadth of cross-neutralization within DENV 309
serocomplex. 310
Collectively, these results demonstrate that a mid-convalescence to ZIKV provokes a 311 boost of the magnitude and durability of the neutralizing response against all DENV serotypes 312 more effectively than in animals with an early-convalescence to ZIKV, but also higher compared 313 to a de novo DENV-specific NAb response of the naïve animals. 314 315 ZIKV neutralization is boosted by DENV infection. Previous exposure to ZIKV strains in 316 ZIKV-immune groups developed high levels of cross-reactive, non-neutralizing, and neutralizing 317
Abs before DENV infection (baseline). To determine if this memory Ab response is strain-318 specific and if the difference in convalescence period to ZIKV alters the efficacy and modulation 319 after DENV infection, we assessed the NAb levels in ZIKV-immune (ZIKVPF-10mo and 320 ZIKVPR-2mo) and ZIKV-naïve serum with both pre-infecting contemporary Asian-lineage 321 H/PF/2013 and PRVABC59 ZIKV strains at multiple timepoints after DENV infection. At 322 baseline, both ZIKV-immune groups showed high NAb titers against H/PF/2013 strain, which 323 suggest that irrespective of pre-exposure to different ZIKV strains and different convalescent 324 periods the Ab response remains similarly effective ( Fig. 5a ). As early as day 15 after DENV 325 infection, a potent boost of NAb titers in both ZIKV-immune groups was developed. However, 326 elevated NAb titers were significantly higher in the ZIKVPF-10mo group compared to the 327 ZIKVPR-2mo and naïve groups at day 15 pi (p=0.0005, p<0.0001; Two-way Anova Tukey test) 328 and day 30 pi (p=0.0067, p=0.0012; Two-way Anova Tukey test). As expected, this elevated 329 ZIKV cross-reactive NAb levels decreased gradually overtime after 15 dpi in both ZIKV-immune 330 groups. Nevertheless, the ZIKVPF-10mo group retained higher NAb titers until 90 dpi while the 331 titers of the ZIKVPR-2mo group returned to baseline levels. Of note, the NAb titers of the naïve 332 group were considered as negative in all timepoints and failed to neutralize ZIKV throughout 333 DENV infection even at concentrated levels of the antibodies (Fig. 5a ). These results are 334 confirmed by the behavior of neutralization kinetics by sigmoidal response curves where the 335 ZIKVPF-10mo group retained elevated magnitude of ZIKV neutralization overtime 336 ( Supplementary Fig. 5 ). 337
To determine if the immune memory induced by different ZIKV strains play a role in the 338 modulation of the cross-NAb response triggered by a subsequent DENV infection, NAb titers 339 were measured against both ZIKV strains before and 30 days after DENV infection. The 340 ZIKVPF-10mo group showed significant higher NAb titers against both ZIKV strains compared 341 to the ZIKVPR-2mo group before DENV infection (p=0.0093, p=0.0141; Two-way Anova Tukey 342 test) ( Fig. 5b ). Subsequently, DENV infection promote an equally 8-fold increase of NAb titers 343 against both strains in the ZIKVPF-10mo group, significantly higher than the 4-fold increase in 344 the ZIKVPR-2mo group (p=0.0025, p=0.0011; Two-way Anova Tukey test) ( Fig. 5c ). To rule out 345 that difference in fitness between both ZIKV strains would bias the magnitude of the NAbs after 346 DENV infection we compared in parallel the NAb titers at 30 and 60 days after ZIKV infection 347 (day 60 correspond to the baseline of the ZIKVPR-2mo group). No significant differences were 348 observed between ZIKV-immune groups in the NAb titers induced by both strains at the same 349 timepoints after ZIKV infection ( Supplementary Fig. 6 ). Altogether, these results demonstrate 350 that DENV infection results in a significant increase in the magnitude and durability of the cross-351
neutralizing Ab response against ZIKV in animals with a mid-convalescent period from ZIKV 352 infection. The elicited changes in neutralization capacity were likely driven more by the longevity 353 of the immune memory maturation and the associated memory recall of the ZIKV immunity than 354 by a strict dependency of the specific pre-exposed ZIKV strain. 355 356 Immune cell subsets modulated by ZIKV immunity. We performed immunophenotyping by 357 flow cytometry to assess the frequency, early activation and proliferation of multiple immune cell 358 subsets and how these parameters are affected by the presence of pre-existing immunity to 359 ZIKV on a subsequent DENV infection ( Supplementary Fig. 7 , 8, and 9 for gating strategy; 360 Supplementary Table 2 for Ab panel). As part of the innate immune response, the frequency of 361 dendritic cells (DCs) and natural killer (NK) cells subpopulations were measured. Plasmacytoid 362 DCs (pDCs: Lin -HLA-DR + CD123 + ) are known to respond to viral infection by production of IFN-363 α, while myeloid DCs (mDCs: Lin -HLA-DR + CD11c + ) interacts with T cells. The frequency of 364 pDCs was not significantly altered by DENV infection in any group compared to baseline levels 365 ( Supplementary Fig. 10a ). At day 2 pi we detected a significant increase of mDCs in the 366 ZIKVPF-10mo group (p=0.0082; Two-way Anova Dunnett test) ( Supplementary Fig. 10b ). 367 Furthermore, we determined the frequency of NK subpopulations including: NKCD8, NKCD56, 368
NKp30 and NKp46 ( Supplementary Fig. 11 ). In general, no differences were detected between 369 baseline and after DENV infection in all groups for all NK subpopulations and receptor 370 expression with the exception of the ZIKVPR-2mo group that showed a significant increases in 371 the following subpopulations: NKG2A + NKp30 and NKp30 + NKp46 + at 7 dpi (p=0.0495, p=0.0006; 372
Two-way Anova Dunnett test) and NKp46 + NKp30 + at 7 and 10 dpi (p=0.0005, p=0.0001; Two-373 way Anova Dunnett test) ( Supplementary Fig. 11j , o, s). 374
We next investigated cell subsets that are part of the bi-phasic (humoral/cellular) 375
adaptive immune response such as B (CD20+CD3-) and T (CD3+CD20-) cells. No differences 376 were detected in total B cells between groups following DENV infection compared to baseline 377 levels ( Supplementary Fig. 12a ), but ZIKV-immune groups had elevated levels of activated B 378 cells (CD20+CD3-CD69+) since baseline and a trend to increase these levels more than the 379 naïve group overtime ( Supplementary Fig. 12b ). We detected a significant decrease of 380 proliferating B cells (CD20+CD3-Ki67+) in naïve animals at 7 and 10 dpi (p=0.0031, p=0.0345; 381
Two-way Anova Dunnett test), while ZIKV-immune groups retained their proliferating levels 382 ( Supplementary Fig. 12c ). Interestingly, the ZIKVPF-10mo group showed a significant increase 383 of B cells that were proliferating and activated simultaneously (CD20+CD3-CD69+Ki67+) as 384 early as in day 1 pi (p=0.0240; Two-way Anova Dunnett test) and maintained higher levels up to 385 10 dpi ( Supplementary Fig. 12d ). Together, these phenotyping results of B cells are consistent 386 with the early and boosted production of binding and neutralizing Abs in the ZIKVPF-10mo 387 group compared to naïve animals. The frequency of total T cells (CD3 + CD20 -) and CD4 + /CD8 + T 388 cells subsets, was comparable at all timepoints before and after DENV infection in all groups of 389 animals ( Supplementary Fig. 13a-c) . 390
Previous studies have demonstrated that DENV and ZIKV specific CD4 + and CD8 + T 391 cells are enriched in certain memory subsets 23,48 . Thus, we measured whether the early 392 activation of T cell subpopulations, such as effector memory (CD3 + CD4 + CD28 -CD95 + ) and 393 central memory (CD3 + CD4 + CD28 + CD95 + ) T cells (T-EM and T-CM), within each T cell 394 compartment was modulated following DENV infection in presence or absence of 395 convalescence to ZIKV ( Fig. 6 , and Supplementary Fig. 7 for gating strategy). The ZIKVPF-396 10mo group showed significant higher frequency of activated CD4 + and CD8 + T-EM 397 (CD3 + CD4 + CD28 -CD95 + CD69 + and CD3 + CD8 + CD28 -CD95 + CD69 + ) following DENV infection 398 compared to basal levels (CD4 + T-EM at 7 and 10 dpi: p=0.0001, p=0.0072; CD8 + T-EM at 2 and 399 7 dpi: p=0.0291, p=0.0001; Two-way Anova Dunnett test) ( Fig. 6a, d) . Interestingly, the 400 ZIKVPR-2mo group showed a very limited frequency and activation of the CD4 + and CD8 + T-EM 401 compared to the ZIKVPF-10mo and naïve groups. However, this group with an early 402 convalescent period to ZIKV, contrary to the other two groups, showed a very limited but 403 significant activation of CD8 + T-CM (CD3 + CD8 + CD28 + CD95 + CD69 + ) at day 7 and 10 pi 404 (p=0.0007, p=0.0147; Two-way Anova Dunnett test) ( Fig. 6e ). In contrast, naïve animals did not 405
show any significant activation of these memory cell subsets after DENV infection. Collectively, 406 these results suggest that following DENV infection: (i) animals with a mid-convalescence ZIKV 407 immunity have a more dynamic B cell response and are able to rapidly produce more activated 408 PBMCs were isolated and stimulated with peptide pools from DENV and ZIKV envelope (E) 419 proteins and from ZIKV non-structural proteins (ZIKV-NS) ( Supplementary Table 4 for peptide 420 sequences). Then, intracellular cytokine staining using flow cytometry analysis (Supplementary 421 Supplementary Table 3 for Ab panel) was performed to quantify the 422 production of effector immune markers such as the cytotoxic marker CD107a, IFN-γ, and TNF-α 423 by CD4 + and CD8 + T cells at baseline, 30, 60, and 90 days after DENV infection ( Fig. 7) . 424
To assess the ZIKV-primed specific-or cross-reactive effector T cell response we 425 studied the response against ZIKV or DENV stimuli before DENV infection. In general, before 426 DENV infection, we found that the ZIKV-primed effector T cell response was higher in CD8 + 427 ( Fig. 7m , q, u) than in CD4 + (Fig 7a, After DENV infection, we were able to determine the modulation of the ZIKV-primed 439 effector CD4 + and CD8 + T cell responses of ZIKV-immune groups and the de novo response of 440 ZIKV-naïve animals. The ZIKVPF-10mo and naïve groups significantly boosted their CD107a 441 expression in both T cell compartments stimulated mainly by DENV E protein at 30 and up to 90 442 days after DENV infection (CD4 + T cells: ZIKVPF-10mo vs ZIKVPR-2mo: p<0.0001 at 30 dpi, 443
p<0.0001 at 60 dpi; Naïve vs ZIKVPR-2mo: p<0.0001 at 30 dpi, p=0.0018 at 60 dpi; ZIKVPF-444 10mo vs Naïve: p=0.0204 at 30 dpi. CD8 + T cells: ZIKVPF-10mo vs ZIKVPR-2mo: p<0.0001 at 445 30 dpi, p<0.0001 at 60 dpi, p=0.0008 at 90 dpi; Naïve vs ZIKVPR-2mo: p=0.0039 at 30 dpi, 446
p<0.0001 at 60 dpi; p=0.0081 at 90 dpi; ZIKVPF-10mo vs Naïve: p=0.0194 at 30 dpi; Two-way 447
Anova Tukey test) ( Fig. 7b , c, n, o, p). Also, these groups boosted the CD107a cytotoxic 448 signature reacting against ZIKV E and NS proteins by cross-reactive CD4 + T cells 30 days after 449 DENV infection (ZIKVPF-10mo vs ZIKVPR-2mo: p=0.0025 for ZIKV E, p<0.0001 for ZIKV NS; 450
Naïve vs ZIKVPR-2mo: p=0.0025 for ZIKV E, p=0.0002 for ZIKV NS; Two-way Anova Tukey 451 test) ( Fig. 7b) . 452
The ZIKVPF-10mo group showed a remarkable significant increase of the IFN-γ-453 producing CD4 + T cells against DENV E protein since 60 dpi and is maintained up to 90 dpi 454 compared to other groups (ZIKVPF-10mo vs ZIKVPR-2mo at 60 and 90 dpi: p<0.0001, 455 p=0.0024; ZIKVPF-10mo vs Naïve at 60 and 90 dpi: p<0.0001, p=0.0037; Two-way Anova 456
Tukey test) ( Fig. 7g, h) , and was the only group with significant increase in the IFN-γ producing 457 CD8 + T cell compartment at 60 dpi (ZIKVPF-10mo vs ZIKVPR-2mo: p=0.0253; Two-way Anova 458
Tukey test) ( Fig. 7s ). On the other hand, the ZIKVPR-2mo group exhibited a significant increase 459 of IFN-γ producing CD4 + T cells earlier than other groups at 30 dpi (ZIKVPR-2mo vs ZIKVPF-460 10mo: p<0.0001; ZIKVPR-2mo vs Naïve: Two-way Anova Tukey test) ( Fig. 7f ). Interestingly, the 461 naïve group showed an increase of cross-reactive TNF-α producing CD4 + T cells against ZIKV 462 NS proteins 30 days after DENV infection (Naïve vs ZIKVPR-2mo: p=0.0359; Two-way Anova 463
Tukey test) (Fig. 7j ). The ZIKVPF-10mo group developed a significant effector T cell response 464 by TNF-α producing CD4 + T cells against DENV and ZIKV E proteins at 60 days after DENV 465 infection (ZIKVPF-10mo vs ZIKVPR-2mo against DENV/ZIKV E protein: p=0.0163, p=0.0172; 466
Two-way Anova Tukey test) ( Fig. 7k ). Although all groups showed a boosted TNF-α effector 467 response in the CD8 + T cell compartment up to 90 days after DENV infection, no significant 468 differences between groups were observed. 469
Collectively, these results after DENV infection suggest that a mid-convalescence to 470 ZIKV translate in a more complete functional T cell response characterized by: (i) a cytotoxic 471 RNAemia, regardless of the period of convalescence from previous ZIKV infection (10 or 2 501 months) and different pre-infecting ZIKV strains. Previous ZIKV immunity is associated with a 502 trend of less RNAemia days during subsequent DENV infection. This effect is more evident in 503 animals with a ZIKV convalescence period of 10 months. Previous work reported that a period 504 of early-convalescence (56 days) to ZIKV (PRVABC59 strain) in rhesus macaques was 505 associated with a significant increase of DENV-2 RNAemia at day 5 after DENV infection and a 506 pro-inflammatory cytokine profile. However, very similar to our results, it was noteworthy a delay 507 at early timepoints and an early clearance in late timepoints of the DENV-2 RNAemia in ZIKV-508 immune macaques in comparison to the naïve ones 37 . The lack of significant DENV RNAemia 509 enhancement found in the group with the early-convalescence period in our work, compared to 510 previous results 37 , may be attributable to the different sample types collected (plasma vs 511 serum), or different DENV-2 strains used for the challenge [New Guinea/1944 strain vs 512
Thailand/16681/1964 strain, from Asian II and Asian I Genotype, respectively]. This fact is of 513 relevance because it suggests that the effect of previous ZIKV immunity on a subsequent DENV 514 infection may differ between DENV serotypes or even within genotypes. Another possible 515 explanation is the genetic heterogeneity of rhesus macaques used in these two studies as they 516 are derived from different breeders. The importance of selecting genetic well-characterized 517 macaques have been discussed previously 49 . 518
Due to limited availability of ZIKV-immune cohorts we used animals infected with two 519 different ZIKV strains for our subsequent challenge with DENV-2. However, extensive revision 520 of the literature up to date reveals a broad consensus that these two contemporary ZIKV strains 521 behave very similar from an antigenic point of view 11,50-52 . Our results are confirmatory of those 522 results showing that both ZIKV strains were neutralized with same efficacy by serum within each 523 ZIKV-convalescent group, explained by the broadly neutralization activity against multiple ZIKV 524 strains irrespective of the infecting strain 51 . However, the magnitude of the neutralization of both 525 strains was statistically higher in animals exposed to DENV 10 months (mid-convalescence) 526 after ZIKV infection compared to the animals with a shorter ZIKV convalescence (2 months). 527
These results suggest that the differences in the neutralization profile between the two ZIKV-528 immune groups are associated to the longevity of ZIKV convalescence which may be 529 attributable to the maturation of the cross-reactive immune memory elicited by the heterologous 530 DENV infection and no to the antigenic differences or the different replication capabilities in 531 rhesus macaques of those two pre-infecting ZIKV strains 16, 53 . 532
The period of convalescence further had an impact in the maintenance of the 533 neutralization magnitude against ZIKV and DENV overtime. We observed a higher activation of 534 the memory immune response characterized by transiently higher peak levels of serum NAbs 535 against DENVs and ZIKV in ZIKVPF-10mo immune animals compared to ZIKVPR-2mo immune 536 animals challenged with DENV-2. However, unlike heterologous infections with different DENV 537 serotypes, by 90 days after DENV-2 infection, the naïve and ZIKV-immune animals had similar 538 levels of DENV-2 NAbs. On the other hand, ZIKV NAbs decay overtime in ZIKV-immune 539 animals after DENV infection, but animals with longer convalescence retain higher titers until the 540 end of the study. Overall, these results demonstrate that pre-existing ZIKV immunity leads to a 541 transient increase in neutralizing Ab responses in animals challenged with DENV-2 compared to 542 naïve animals. This is in contrast with previous findings were ZIKV-convalescent macaques 543
show a lack of an early and delayed anamnestic response overtime with limited induction of 544 DENV NAbs compared to ZIKV-naïve animals after DENV infection 54 . However, our results 545
show the ability of DENV-2 to activate MBCs stimulated by the previous ZIKV infection, but this 546 activation is modest and short-lived compared to the robust and sustained activation of MBCs 547 on secondary DENV infections 10,30,46,55 . Is still uncertain why the ZIKVPF-10mo animals have a 548 slightly higher peak of Ab response compared to the ZIKVPR-2mo animals. We speculate this 549 may be caused by modification of MBCs overtime, so that by 10 months the cells are able to 550 better respond to antigen compared to cells at two months. After ZIKV infection in human infected human subjects showed low cross-neutralization against all DENV serotypes, but 564 DENV-4 followed by DENV-2 were neutralized more efficiently up to 6 months after ZIKV 565 infection with comparable basal titers reported here 58 . There is no data yet that delineates 566 shared cross-neutralizing epitopes between ZIKV and DENV-2/-4, but it is known that DENV-4 567 genotypic diversity impact the capacity of its neutralization 59 . 568
Early studies of T cells associate their contribution towards immunopathogenesis in 569
DENV secondary infections explained by the original antigenic sin 60 , but increasing evidence 570 suggest their protective role during primary and secondary DENV infections 61 . Recently, with the 571 introduction of ZIKV into The Americas, T cells from DENV immunity are being implicated in 572 mediating cross-protection against ZIKV 21-23 . We found that animals with a mid-convalescence 573 to ZIKV developed an early activation of CD4 + and CD8 + effector memory T cells after DENV 574 infection. This early activation has been observed for the opposite scenario in DENV-immune 575 ZIKV-infected patients 23 . Interestingly, the ZIKV early-convalescent group displays a modest 576 activation (T-CM>T-EM) early after DENV infection. Since this group was infected with ZIKV 577 only two months before DENV it is possible that after viral clearance and development of ZIKV-578 specific T cell response, the T cell compartments were still under the contraction phase at the 579
time of the DENV challenge. Yellow fever virus (YFV) and vaccinia virus vaccinations in humans 580
demonstrate that T cell contraction start as early as approximately one-month post-vaccination 581 and at least for almost three months is still ongoing 62 . Also, a study shows that re-stimulation 582 using alphavirus replicons during T cell response contraction does not have significant impact 583 modulating the pre-existing T cell response 63 . 584
The profile of ZIKV-specific CD8 + T cells in humans with convalescence to ZIKV is 585 characterized by the production of IFN-γ, and expression of activation and cytotoxic markers 64 . 586
Presence of sustained levels of IFN-γ prior and early after DENV challenge in vaccinees has 587 been associated with protection against viremia and/or severe disease 65,66 . We observed a 588 similar phenotype of the functional response of CD8 + T cells prior DENV infection in animals 589 with longer convalescence to ZIKV. Strikingly, this response recognizes more efficiently 590 peptides from DENV E protein than from ZIKV E protein. However, ZIKV-specific CD8 + T cells 591 direct 57% of their response against structural proteins, which may suggest these cells can 592 recognize conserved epitopes between ZIKV and DENV structural proteins. Cross-reactivity of T 593 cells between heterologous flavivirus infections is explained by selective immune recall of 594 memory T cells that recognize conserved epitopes between DENV and ZIKV 23 , which also has 595 previously been demonstrated during secondary heterotypic DENV infections 67,68 . In addition, an 596 increased cytotoxic profile as demonstrated by the higher frequency of CD107a-expressing 597 CD4 + and CD8 + T cells in the ZIKV mid-convalescent group correlates with the synchronously 598 early activation of CD4 + and CD8 + effector memory T cells and elevated levels of perforin 599
release. 600
Higher proportion of IFN-γ and TNF-α producing T cells before a secondary 601 heterologous DENV infection has been associated to a subsequent subclinical outcome 69 . 602
Herein, we observed that the ZIKV mid-convalescent group had elevated levels of IFN-γ and 603 TNF-α producing T cells since baseline. In this group, DENV infection stimulated a higher 604 frequency of these cells, but remarkably, also increased highly cross-reactive IFN-γ-producing 605
CD4 + T cells directed to DENV E, and ZIKV E/NS proteins. Memory CD4 + T cells are required to 606
generate an effective humoral response against ZIKV 70 . Based on this, the higher proportion of 607 DENV-E-reactive IFN-γ-producing CD4 + T cells may play a role in the induction of the robust Ab 608 response in the ZIKV mid-convalescent group against ZIKV and all DENV serotypes. On the 609 other hand, we showed that naïve animals with DENV de novo response did not cross-610 neutralized ZIKV at all, which state that although similar, antigenic differences are sufficient to 611 mount predominantly type-specific rather than cross-reactive responses during a primary 612 infection 50,56 . 613
A lack of ZIKV immunity promoted a more pro-inflammatory profile after DENV infection 614 characterized by significant elevated levels of IL-6 and MIG/CXCL9. Interestingly, higher levels 615 of IFN-α were observed in the ZIKV-naïve animals. This antiviral cytokine is known to be 616 actively produced during acute DENV infection in vitro and in vivo 71 . Elevated levels have been 617 correlated with severity in DHF patients, and to act as a marker for elevated DENV 618 replication 72,73 . On the other hand, the presence of a longer ZIKV convalescence is associated 619 with increased levels of CXCL10 and perforin. CXCL10 is an immune mediator for T cells 620 proliferation, recruitment of CD4 + and CD8 + activated T cells and IFN-γ-producing CD8 + T cells, 621 required to control DENV infection in vivo 74,75 . This correlates with higher proportion and 622
activation of both T cell compartments and subsequent functional T cell response against 623
DENV-E-specific peptides in the group with longer convalescence to ZIKV. Perforin is involved 624 in the cytotoxic degranulation process against virus-infected cells. In DENV infection, perforin is 625 part of the anti-DENV cytotoxic phenotype of CD8 + and CD4 + T cells 48, 76 . Perforin levels were 626 significantly elevated only in the ZIKV mid-convalescent group after DENV infection. 627
Accordingly, this coincides with a significant activation of CD8 + and CD4 + effector memory T 628 cells, and degranulation functional response of both T cell compartments, suggesting an 629 enhanced perforin-producing cytotoxic role of T cells in presence of longer convalescence to 630 ZIKV. Contrary to our findings, a previously published work found that an approximately two 631 month ZIKV immunity period resulted in an increase of pro-inflammatory cytokines 37 . However, 632 a differential effect due to the use of different sample types (plasma vs serum) between both 633 studies cannot be ruled out. This study reinforces the usefulness of NHPs as a suitable model to characterize the 660 immune response elicited by heterologous and consecutive flavivirus infections and to identify 661 differential modulation of the immune response influenced by the time interval between 662 infections. Our findings of highly cross-reactive response against DENV in presence of previous 663 ZIKV immunity with no exacerbation of DENV pathogenesis may contribute to explain the 664 decrease of detected DENV cases after ZIKV epidemic in the Americas. This scenario has been 665 suggested recently using a fewer number of animals 38 . Furthermore, our data show a positive 666 scenario that supports the implementation of ZIKV vaccine programs, since it suggests that a 667 vaccine-acquired ZIKV-immunity may not worsen DENV pathogenesis and may ameliorate 668 immune response against a subsequent infection with DENV. Similarly, the implementation of 669 DENV vaccines is also supported in the context of previous ZIKV immunity, since ZIKV 670 convalescence may boost the vaccine-acquired anamnestic immune response to DENV without 671 predisposing to an enhanced pathogenesis. However, the selection of the vaccine schedule 672 may be critical to induce the optimal immune response when more than one doses are planned. for the challenge in order to obtain comparative results with previous published studies from our 690 group on DENV and ZIKV challenge studies 16, 33 . We have standardized the assays to quantify 691 this virus by Plaque assay, as described in our previous work 16 Plates were incubated for 1 hr, 37°C, 5% CO 2 and rocking. After incubation, virus dilutions were 704 overlaid with 1 ml of Opti-MEM [1% Carboxymethylcellulose (Sigma), 2% FBS, 1% of NEAA 705 (Gibco) and P/S (Gibco)]. After 3 to 5 days of incubation (days vary between DENV serotypes), 706 overlay was removed and cells were washed twice with phosphate buffered saline (PBS), fixed 707 in 80% methanol (Sigma) in PBS, and incubated at room temperature (RT) for 15 minutes. 708
Plates were blocked with 5% Non-fat dry milk (Denia) in PBS for 10 minutes. timelines and also naïve cohorts were available as well. After our laboratories prioritized ZIKV 724 research since 2016, DENV pre-exposed and naïve cohorts were infected with ZIKV and pre-725 exposed animals became available for this study. All animals were housed within the Animal 726 The experimental design was based on 14 young adult male rhesus macaques divided 740 in three cohorts. Cohort 1 (ZIKVPF-10mo): composed of four animals (5K6, CB52, 2K2, and 741 6N1) that were inoculated with 1x10 6 pfu/500 ul of the ZIKV H/PF/2013 strain subcutaneously 16 742 10 months before DENV-2 challenge. Cohort 2 (ZIKVPR-2mo): composed of 6 animals (MA067, 743 MA068, BZ34, MA141, MA143, and MA085) that were inoculated with 1x10 6 pfu/500 ul of the 744 ZIKV PRVABC59 strain two months before DENV-2 challenge. Both ZIKV strains used for 745 previous exposure of these groups are >99.99% comparable in amino acid identity 746
( Supplementary Table 1 ). Cohort 3 (Naïve): composed of four ZIKV/DENV naïve animals 747 (MA123, MA023, MA029, and MA062) as a control group. Cohort 1 and 3 were challenged on 748 the same day while cohort 2 was challenged 3 months later with the same stock of DENV-2. 749
However, all samples were frozen and analyzed together, except for the immunophenotyping 750
analysis. 751
The ages of all animals are within the age range for young adults rhesus macaques 752 https://www.nc3rs.org.uk/macaques/macaques/life-history-and-diet/ (ZIKVPF-10mo: 6.8, 6.8, 753 5.8, and 5.9; ZIKVPR-2mo: 6.4, 6.5, 5.2, 4.3, 5.6, and 5.5; Naïve: 4.8, 6.6, 6.8, and 5.7). Prior to 754 DENV-2 challenge all animals were subjected to quarantine period. All cohorts were bled for 755 baseline and challenged subcutaneously (deltoid area) with 5x10 5 pfu/500 ul of DENV-2 New 756 Guinea 44 strain. After DENV-2 challenge all animals were extensively monitored by trained and 757 certified veterinary staff for evidence of disease and clinical status: external temperature (°C) 758 with an infrared device (EXTECH Instruments, Waltham, MA), weight (Kg), CBC and CMP. All 759 animals were bled once daily from day 1 to day 10 and after that on days 15, 30, 60 and 90 760 post-infection (dpi). In all timepoints the blood samples were used for serum separation 761 (Baseline, 7, 30, 60, 90 dpi only). PBMCs were collected at same time points using CPT tubes 762 (BD-Biosciences, San Jose, CA) containing citrate. Additional heparin samples were obtained 763 for immunophenotyping by flow cytometry using fresh whole blood. Fig. 1 shows the 764 experimental design and samples collection timeline. serotype (DENV-2) and ZIKV the NAbs were measured in early timepoints as well (7 and 15 802 dpi). For the PRNT, serum samples were inactivated, diluted (2-fold), mixed with a constant 803 inoculum of virus (volume necessary to produce ~35 pfu/well) and then incubated for 1 hr at 804 37°C and 5% CO 2 . After incubation, virus-serum mix dilutions were added to Vero-81 cells 805 monolayer in flat bottom 24-well plates seeded the day before for 1 hr at 37°C and 5% CO 2 , 806 finally overlay medium was added and incubated by several days (serotype dependent). Results 807 were reported as PRNT60 titers, NAb titer capable of reduce 60% or more of DENV serotypes 808 or ZIKV strains pfu compared with the mock (control of virus without serum). A PRNT60 1:20 809 titer was considered a positive Neut titer, and <1:20 as a negative Neut titer. Non-neutralizing 810 titers (<1:20) were assigned with one-half of the limit of detection for graphs visualization. 811 812 Multiplex Cytokine Profile. A total of 8 cytokines/chemokines were measured (pg /ml -1 ) by 813
Luminex at baseline, 1, 2, 3, 5, 10, 15 and 30 dpi, including: interferon alpha (IFN-α), 814
interleukin-6 (IL-6), monokine induced by IFN-gamma (MIG/CXCL9), monocyte chemoattractant 815 protein 1 (MCP-1/CCL2), macrophage inflammatory protein 1-beta (MIP-1β/CCL4), IL-1 816 receptor antagonist (IL-1RA), C-X-C motif chemokine 10 (CXCL10/IP-10) and perforin. The 817 multiplex assay was conducted as previously described 16, 79 . 818
819
Immunophenotyping. Flow cytometry (MACSQuant Analyzer 10, Miltenyi Biotec) analysis was 820 performed to determine the frequency, activation and proliferation of cell populations of the 821 innate and adaptive immune response based on the phenotyping strategy of a previous study 16 822 ( Supplementary Fig. 7, 8 , and 9 for gating strategy; Supplementary Table 2 for Ab panel). NKG2A, NKp30, and NKp46 ( Supplementary Fig. 9 for gating strategy). Dendritic cells (DC) 837
were separated in two populations within the Lineage-DR+ (HLA-DR + CD3 -CD14 -CD16 -CD20 -838 CD8 -NKG2A -) by the expression of CD123 (plasmacytoid, pDC) or CD11c (myeloid, mDCs) 839 ( Supplementary Fig. 8 for gating strategy). Then, DC percentages were calculated from total 840 PBMCs (total events of the DC subpopulation divided by total PBMCs and multiplied by 100). 841
The phenotyping assays were optimized and performed as previously published 16, 33, 80 . 842 843 T Cell Functional Response. Intracellular cytokine staining of macaques PBMCs was 844 performed by multicolor flow cytometry using methods previously described (Supplementary 845 Supplementary Table 3 for Ab panel) 16, 80 . Functional effector 846 response of CD4 + and CD8 + T cells was measured before and after DENV infection. Antigen-847 specific CD4 + and CD8 + T cell effector responses were measured at baseline to determine basal 848 levels in presence (ZIKVPF-10mo, ZIKVPR-2mo) or absence (Naïve) of previous immunity to 849 ZIKV. Also, 30, 60 and 90 dpi were assessed to determine how this pre-existing functional 850 response is modulated after DENV infection and if is maintained over time. For peptide pools 851 stimulation, PBMCs were stimulated for 6 hr at 37°C and 5% CO 2. The peptides used for DENV-852 E, ZIKV-E and ZIKV-NS were 15-mers overlapped by 10 amino acids at 1.25 ug/ml -1 , 2.5 ug/ml -853 1 , 475 ng/ml -1 per peptide, respectively ( Supplementary Table 4 for peptide sequences). The 854 stimulation with peptides was performed in presence of brefeldin A at 10 ug/ml -1 . After 855 stimulation, the cells were stained for the following markers: CD3, CD4, CD8, CD20 (excluded), 856
CD107a (functional cytotoxicity). Levels of IFN-γ and TNF-α also were measured in gated 857 lymphocytes cell populations. Samples were measured and data was collected on a LSRII (BD). 
